当前位置: X-MOL 学术ACS Appl. Mater. Interfaces › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Photothermal Fenton Nanocatalysts for Synergetic Cancer Therapy in the Second Near-Infrared Window.
ACS Applied Materials & Interfaces ( IF 9.5 ) Pub Date : 2020-06-09 , DOI: 10.1021/acsami.0c07013
Haitao Sun 1 , Yaying Zhang 2 , Siyu Chen 3 , Ruizhi Wang 1 , Qian Chen 4 , Jingchao Li 5 , Yu Luo 6 , Xiaolin Wang 1 , Hangrong Chen 4
Affiliation  

Chemodynamic therapy (CDT) that utilizes endogenous hydrogen peroxide (H2O2) to produce reactive oxygen species (ROS) to kill cancer cells has shown a promising strategy for malignant tumor treatment. Nevertheless, limited H2O2 levels in the tumor microenvironment often compromise the therapeutic benefits of CDT, leading to cancer recurrence and metastasis. Herein, a second near-infrared (NIR-II) photothermal Fenton nanocatalyst (PFN) was developed for activatable magnetic resonance imaging (MRI)-guided synergetic photothermal therapy (PTT) and CDT of pancreatic carcinoma. Such a PFN consists of manganese dioxide (MnO2), copper sulfide (CuS), and human serum albumin (HSA), which serve as the activatable imaging contrast agent, the NIR-II photothermal agent and Fenton catalyst, and the stabilizer, respectively. The acidic tumor microenvironment increased the relaxivity of PFN by 2.1-fold, allowing for improved imaging performance and monitoring of nanoparticle accumulation in tumors. Under NIR-II laser irradiation at 1064 nm, PFN generates local heat, which not only permits PTT but also enhances the nanocatalyst-mediated Fenton-like reaction. As such, PFN exerts a synergetic action to completely ablate xenografted tumor models in living animals, while the sole CDT fails to do so. This study thus provides an NIR-II photothermal nanocatalyst for potential treatment of deep-seated tumors.

中文翻译:

在第二近红外窗口中用于协同癌症治疗的光热Fenton纳米催化剂。

利用内源性过氧化氢(H 2 O 2)产生活性氧(ROS)杀死癌细胞的化学动力疗法(CDT)已显示出用于恶性肿瘤治疗的有前途的策略。然而,肿瘤微环境中有限的H 2 O 2水平经常损害CDT的治疗益处,导致癌症复发和转移。本文中,第二种近红外(NIR-II)光热芬顿纳米催化剂(PFN)被开发用于胰腺癌的可激活磁共振成像(MRI)引导的协同光热疗法(PTT)和CDT。这种PFN由二氧化锰(MnO 2),硫化铜(CuS)和人血清白蛋白(HSA)(分别用作可激活的成像造影剂,NIR-II光热剂和Fenton催化剂以及稳定剂)。酸性肿瘤微环境使PFN的弛豫度提高了2.1倍,从而改善了成像性能并监测了肿瘤中纳米颗粒的积累。在1064 nm的NIR-II激光照射下,PFN产生局部热量,不仅允许PTT发生,而且还增强了纳米催化剂介导的Fenton样反应。因此,PFN发挥了协同作用,可以完全消融活体动物的异种移植肿瘤模型,而唯一的CDT则不能。因此,这项研究为潜在治疗深部肿瘤提供了一种NIR-II光热纳米催化剂。
更新日期:2020-07-08
down
wechat
bug